Shares of Bliss GVS Pharma climbed by 5% on Monday, reaching an intraday high of ₹138.20, following the company’s announcement of a significant achievement. The pharmaceutical company secured Good Manufacturing Practice (GMP) certification for two of its manufacturing facilities from the National Agency for Medicines and Medical Devices of Romania (NAMMDR).
According to an exchange filing made on Saturday, the certified facilities are located at Plot No. 11, Dewan Udyog Nagar, Aliyali Village, and Survey No. 43-44, Vevoor Village, both in Palghar, India. This certification was granted after an EU GMP inspection conducted on November 30 and December 1, 2023.
The recognition strengthens the company's reputation in the pharmaceutical sector and underscores its commitment to quality manufacturing standards, which is critical for investors considering share market investment in the healthcare sector.
Q2 financial performance: A mixed picture
Bliss GVS Pharma's second-quarter results for FY2024-25 revealed a mixed financial performance. The company reported a year-on-year consolidated revenue decline of 2.8%, totalling ₹217 crore. However, quarter-on-quarter revenue surged by 18%, indicating a strong recovery compared to the previous quarter.
Despite the revenue growth, net profit fell by 41% year-on-year, dropping to ₹25 crore from ₹43 crore in the same period last year. On a quarterly basis, net profit rose by 13.6%, showcasing resilience amid challenging market conditions. These financial trends highlight the importance of diligent analysis when making share market investments, especially in sectors prone to fluctuating performance.
Stock performance and market position
Bliss GVS Pharma's stock performance has been relatively subdued in 2024. The stock has gained 8% year-to-date but experienced an 8% decline over the past year, underperforming compared to the broader market. In contrast, the BSE Sensex recorded a 21% annual increase and an 11% year-to-date rise, reflecting stronger overall market growth.
The company's current market capitalisation stands at ₹1,414.19 crore. With a price-to-earnings (P/E) ratio of 30.24 and earnings per share (EPS) of ₹4.35, the stock presents an opportunity for those focusing on share market investment in niche pharmaceutical firms with growth potential.
Market reaction and investor sentiment
As of 10:45 AM on Monday, Bliss GVS Pharma shares were trading 2.28% higher at ₹134.50, outperforming the BSE Sensex, which was up by 1.55% at 80,343.97. The positive market sentiment following the EU GMP certification signals confidence in the company’s ability to meet international quality standards. This development could drive greater interest from investors exploring opportunities in the pharmaceutical sector.
Implications for share market investment
Bliss GVS Pharma's achievement of EU GMP certification reflects its dedication to high manufacturing standards, which can bolster its global reputation and competitiveness. For investors, the certification could serve as a potential growth catalyst, enhancing the company's prospects for international expansion.
Moreover, the stock's performance metrics, including its recent price movements and financial results, highlight the importance of analysing both short-term gains and long-term growth potential. Investors focusing on share market investment may view this milestone as a promising opportunity, provided they account for the inherent risks in the volatile healthcare sector.
Bliss GVS Pharma's journey underscores the significance of strategic decision-making in share market investment, especially when selecting stocks in industries poised for innovation and growth.
For android only